Onco-Metabolic Surgery: A Combined Approach to Gastric Cancer and Hypertension

This article was published in the following Dove Press journal:
Cancer Management and Research

Dong Peng*  
Yu-Xi Cheng*  
Wei Tao  
Ying-Ying Zou  
Kun Qian  
Wei Zhang

Department of Gastrointestinal Surgery,  
The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, People’s Republic of China

*These authors contributed equally to this work

Purpose: The purpose of this study was to explore the changes in blood pressure in patients with concurrent gastric cancer and hypertension after gastrectomy, and to identify the factors that affect the changes in blood pressure.

Materials and Methods: Patients with concurrent gastric cancer and hypertension who underwent gastrectomy were retrospectively analyzed from January 2013 to December 2018. The pre- and 6-month postoperative medical records were compared. Predictors for the remission of hypertension were analyzed.

Results: A total of 143 patients with concurrent gastric cancer and hypertension were included in this study. The number of patients with complete remission, partial remission and no remission were 67 (46.9%), 12 (8.4%) and 64 (44.7%), respectively. The average of weight and BMI (body mass index) before gastrectomy were 63.0 ± 9.7 kg and 23.4 ± 2.0 kg/m², respectively, which were significantly higher than those 6-month postgastrectomy: 54.8 ± 9.8 kg and 20.4 ± 3.1 kg/m², respectively (p<0.001). The average number of antihypertensive medications before gastrectomy was 1.5 ± 0.6, while it was 0.8 ± 0.8 6-month postgastrectomy (p<0.001). Age (p<0.05) and the surgical techniques used (p<0.05) were significantly different between partial remission and no remission patients. Furthermore, age (p<0.05) and the surgical techniques used (p<0.05) were significantly different between complete remission and no remission patients. Age (p<0.05, odds ratio =0.933, 95% CI=0.890–0.978) and the surgical techniques used (p<0.05, odds ratio =2.749, 95% CI=1.132–6.677) are predictors for remission of hypertension.

Conclusion: Total gastrectomy is an onco-metabolic surgery that can cure younger patients with concurrent gastric cancer and hypertension. Age and the surgical techniques used can predict the remission of hypertension 6 months after gastrectomy.

Keywords: gastric cancer, age, hypertension, gastrectomy, remission

Introduction
Gastric cancer is the fifth most common cancer in the world and ranks third among cancer-related causes of death. In China, the morbidity and mortality of gastric cancer are growing, and more than 400,000 newly diagnosed cases occur every year. For patients with gastric cancer, gastrectomy is still the most effective treatment. As the survival rate increases, the quality of life of postoperative patients is also a current concern.

Hypertension is a common disease and a major risk factor for cardiovascular disease. It is estimated that 40% of the world’s population suffers from hypertension. Hypertension is also the main global risk factor for death and accounts for 13% of deaths. The number of newly-diagnosed hypertensive patients in China is
rising every year. The management of patients with hypertension also brings a corresponding financial burden.

Much literature has reported the effect of bariatric surgery on blood pressure. A meta-analysis reported that the blood pressure remission rate reached 75% and the complete remission rate reached 58%. However, for patients with concurrent gastric cancer and hypertension, changes in blood pressure after gastrectomy have rarely been reported.

Hence, the purpose of the current study was to retrospectively analyze the changes in blood pressure and the dosages of antihypertensive medications after gastrectomy in patients with concurrent gastric cancer and hypertension, and to explore the parameters for the remission of hypertension after gastrectomy.

Materials and Methods

Patients

A retrospective analysis of patients with gastric cancer who underwent gastrectomy from January 2013 to December 2018 at a single clinical center was conducted. The study was approved by the Institutional Ethics Committee of our hospital, and informed consent was obtained from all patients. Data from a total of 1182 patients were collected and the patients were included according to the following criteria: 1, patients who were diagnosed with gastric cancer through abdominal enhanced CT, gastroscopy and pathological biopsy; 2, patients who underwent gastrectomy; and 3, patients diagnosed with hypertension by a cardiologist and taking antihypertensive medications before gastrectomy. According to the criteria, 315 patients with concurrent gastric cancer and hypertension were included. Patients were excluded from the study according to the following exclusion criteria: 1, incomplete information before gastrectomy (n=16); 2, irregular blood pressure monitoring (n=69); 3, irregular antihypertensive medications use (n=16); 4, death within six months (n=9); 5, no consultation with a cardiologist when changing antihypertensive medications after gastrectomy (n=27); 6, irregular follow-up within 6 months (n=13); 7, presence of secondary hypertension (n=4); and 8, gastric cancer with obstruction (n=18). In total, 143 patients were determined to meet these criteria (Figure 1).

Definitions

Hypertension is defined as an average systolic blood pressure (SBP) ≥140 mmHg or an average diastolic blood pressure (DBP) ≥90 mmHg. The average BP value was based on at least two careful readings on two occasions. Hypertension is classified as Stage I, II or III: an average SBP between 140 and 159 mmHg or an average DBP between 90 and 99 mmHg is regarded as Stage I, an average SBP between 160 and 179 mmHg or an average DBP between 100 and 109 mmHg is regarded as Stage II, and an average SBP ≥180 mmHg or an average DBP ≥110 mmHg is regarded as Stage III. There are five types of common antihypertensive medications according to the guidelines: angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), calcium channel blockers (CCBs), β-blockers and diuretics.

There are three types of remission of hypertension: complete remission, partial remission and no remission. The criteria for complete remission were as follows: 1, an average SBP of <135 mmHg and an average DBP of <85 mmHg observed at least three times on different days without taking antihypertensive medications; and 2, after evaluation by a cardiologist at an outpatient visit, the blood pressure was considered to be normal. The criteria for partial remission were as follows: 1, an average SBP of <135 mmHg and an

![Figure 1](image-url) Inclusion criteria and exclusion criteria of patients with concurrent gastric cancer and hypertension.
average DBP of <85 mmHg observed at least three times on different days after regularly taking antihypertensive medications; and 2, after evaluation by a cardiologist at an outpatient visit, the class or dosages of antihypertensive drugs were reduced, and the blood pressure was controlled in a normal range. No remission was when the class and dosages of antihypertensive medications stayed the same or even increased when the patients consulted a cardiologist after gastrectomy.

**Surgical Techniques**
The surgical techniques were all standard gastrectomy procedures and the types of gastrectomy were based on the location and the size of the tumor. D2 lymph node dissection was performed according to the guideline of the Japanese gastric cancer treatment guidelines 2010 (ver. 3). Billroth I, Billroth II or Roux-en-Y was performed to recover the gastrointestinal continuity.

**Data Collection**
Demographic data were collected by reviewing medical records from the database and through telephone interviews. The preoperative and postoperative data included age, sex, weight, preoperative BMI, comorbid diabetes mellitus (DM), hypertension classification, the class and dosages of antihypertensive medications and the surgical techniques used. Among these data, weight loss refers to the preoperative weight minus the postoperative weight 6 months after gastrectomy, and weight loss% is calculated using the following formula: weight loss/preoperative weight * 100%.

**Statistical Analysis**
The results are shown as the mean values ± standard deviation (SD). Categorical data were analyzed using chi-square tests or Fisher’s exact test, and continuous data were analyzed using independent samples t tests. Paired t tests were also used to examine the differences in continuous variables pre- and 6-month postoperatively. Parameters were selected for multivariate regression analysis for the detection of independent risk factors for the remission of hypertension. Data were analyzed using SPSS (version 20.0) statistical software. A bilateral p value of <0.05 was considered statistically significant.

**Results**
**Baseline Characteristics**
A total of 143 patients with concurrent gastric cancer and hypertension were included in this study. The baseline characteristics of sex, age, comorbid DM, preoperative BMI, preoperative weight, hypertension classification and the class and dosages of antihypertensive medications are shown in Table 1.

**Comparisons of Before and 6 Months After Gastrectomy**
Weight, BMI and antihypertensive medication use were compared before and 6 months after gastrectomy. The average weight and BMI and the number of antihypertensive medications 6 months after gastrectomy were significantly lower than those before gastrectomy (p<0.001) (Table 2).

| Table 1 Baseline Characteristics of Patients with Concurrent Gastric Cancer and Hypertension |
|---------------------------------------------------------------|
| Characteristics                                              | No.143 |
| Sex                                                          |       |
| Male                                                         | 91 (63.6%) |
| Female                                                       | 52 (36.4%) |
| Age (mean ± SD, year)                                        |       |
| DM                                                          | 65.1 ± 8.3 |
| BMI preoperative (mean ± SD), kg/m²                           | 30 (21.0%) |
| Weight preoperative (mean ± SD), kg                          | 23.4 ± 2.9 |
| Hypertension classification (I/II/III)                       | 63.0 ± 9.7 |
| (I)                                                          | 38 (26.5%)/55 (38.3%)/50 (35.0%) |
| Antihypertensive agent (n, %)                                 |       |
| ACEI                                                        | 44 (30.8%) |
| ARB                                                          | 34 (23.8%) |
| CCB                                                         | 99 (69.2%) |
| Beta-blocker                                                 | 17 (11.9%) |
| Diuretics                                                    | 11 (7.7%) |
| Antihypertensive medications (n, %)                          |       |
| 1                                                           | 87 (60.8%) |
| 2                                                           | 48 (33.6%) |
| 3                                                           | 8 (5.6%) |

*Note: Variables are expressed as the mean ± SD or n (%).*  
**Abbreviations:** DM, diabetes mellitus; BMI, body mass index; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.

| Table 2 Comparison Before and 6 Months After Gastrectomy |
|---------------------------------------------------------|
|                                                        | Before       | After        | p          |
| Weight (mean ± SD), kg                                  | 63.0 ± 9.7   | 54.8 ± 9.8   | 0.000*     |
| BMI (mean ± SD), kg/m²                                   | 23.4 ± 2.9   | 20.4 ± 3.1   | 0.000*     |
| Antihypertensive medications (mean ± SD)                | 1.5 ± 0.6    | 0.8 ± 0.8    | 0.000*     |

*Notes: Variables are expressed as the mean ± SD. *P*-value <0.05.  
**Abbreviation:** BMI, body mass index.
Differences Between Remission and No Remission Patients
Seventy-nine (55.3%) patients had hypertension remission, and 64 (44.7%) patients had no hypertension remission. Age, sex, BMI, DM, preoperative weight, weight loss, weight loss %, hypertension classification and the surgical techniques and reconstruction methods used in subtotal gastrectomy were compared between remission and no remission patients. There were significant differences in age (p<0.05) and the surgical techniques used (p<0.05) (Table 3 p²).

Comparison of No Remission, Partial Remission and Complete Remission Patients
Sixty-seven patients (46.9%) had complete hypertension remission, 12 patients (8.4%) had partial hypertension remission, and 64 patients (44.7%) had no hypertension remission. Age, sex, BMI, DM, preoperative weight, weight loss, weight loss%, hypertension classification and the surgical techniques and reconstruction methods used in subtotal gastrectomy were compared between partial remission and no remission patients and between complete remission and no remission patients. Age (p<0.05) and the surgical techniques used (p<0.05) were significantly different between partial remission and no remission patients. Furthermore, age (p<0.05) and the surgical techniques used (p<0.05) were significantly different between complete remission and no remission patients (Table 3 p²).

Multiple Regression Analysis for Remission of Hypertension
Age, weight loss, surgical techniques, hypertension classification and BMI were included in the multiple regression. Age (p<0.05, odds ratio =0.933, 95% CI=0.890–0.978) and the surgical techniques (p<0.05, odds ratio =2.749, 95% CI=1.132–6.677) had statistical significance (Table 4).

Discussion
The remission of hypertensive in patients with concurrent gastric cancer and hypertension after gastrectomy was retrospectively analyzed in this study. The number of patients with complete remission, partial remission and no remission was 67 (46.9%), 12 (8.4%) and 64 (44.7%), respectively. It was found that the postoperative weight, BMI and antihypertensive medication use decreased compared with preoperative parameters. Age and the surgical techniques used were significantly different compared with remission and no remission patients. Furthermore, age and

Table 3 Comparison of No Remission, Remission, Partial Remission and Complete Remission

|                  | No Remission (64) | Remission (79) | Partial Remission (12) | Complete Remission (67) | Total (79) | P²  | P³  | P⁴  |
|------------------|-------------------|---------------|------------------------|-------------------------|------------|-----|-----|-----|
| Age (mean ± SD), year | 67.6 ± 7.5        | 62.3 ± 8.2    | 63.1 ± 8.5             | 63.0 ± 8.4              | 52(36.4%)  | 0.030⁴ | 0.001⁴ | 0.001⁴ |
| Sex Male         | 39(27.3%)         | 9(6.3%)       | 43(30.1%)              | 24(16.8%)               | 27(18.9%)  | 0.518 | 0.721 | 0.602 |
| Female           | 25(17.5%)         | 3(2.1%)       | 23.3 ± 3.1             | 23.5 ± 3.0              | 3(2.1%)    | 0.001⁴ | 0.001⁴ | 0.001⁴ |
| BMI (mean ± SD), kg/m² | 23.4 ± 2.9        | 24.2 ± 2.0    | 24.3 ± 3.1             | 23.5 ± 3.0              | 23.5 ± 3.0 | 0.300 | 0.300 | 0.300 |
| Weight (mean ± SD), kg | 62.0 ± 9.8        | 66.0 ± 6.1    | 63.4 ± 10.1            | 63.8 ± 9.6              | 63.8 ± 9.6 | 0.185 | 0.423 | 0.276 |
| Weight loss (mean ± SD), kg | 7.5 ± 6.2         | 9.8 ± 6.6     | 8.3 ± 6.5              | 8.5 ± 6.5               | 8.5 ± 6.5 | 0.250 | 0.468 | 0.336 |
| Weight loss % (mean ± SD) | 11.8 ± 10.0       | 15.0 ± 10.3   | 12.9 ± 9.8             | 13.2 ± 9.8              | 13.2 ± 9.8 | 0.315 | 0.544 | 0.410 |
| DM               | 13                | 1             | 16                     | 13                      | 13         | 0.047 | 0.623 | 0.860 |
| Hypertension I or II | 38                | 10            | 45                     | 55                      | 55         | 0.192 | 0.371 | 0.221 |
| Classification III | 26                | 2             | 22                     | 24                      | 24         | 0.038⁴ | 0.008⁴ | 0.004⁴ |
| Surgical techniques | 55                | 7             | 44                     | 51                      | 51         | 0.426 | 0.676 | 0.885 |
| Subtotal gastrectomy | 9                 | 5             | 23                     | 28                      | 28         | 0.426 | 0.676 | 0.885 |
| Total gastrectomy  |                   |               |                        |                         |            |      |      |      |

Notes: Variables are expressed as the mean ± SD or n (%). *P-value <0.05, No remission versus Partial remission, No remission versus Complete remission, No remission versus total (partial remission + complete remission).

Abbreviations: BMI, body mass index; DM, diabetes mellitus; B-I, Billroth I reconstruction; B-II, Billroth II reconstruction; R-Y, Roux-en-Y reconstruction.
Table 4 Multiple Regression Analysis for Remission of Hypertension

| Individual Variable | P value | OR (95% CI) |
|---------------------|---------|-------------|
| Age | 0.004* | 0.933 (0.890–0.978) |
| Weight loss | 0.763 | 1.010 (0.949–1.074) |
| Surgical techniques | 0.025* | 2.749 (1.132–6.677) |
| Hypertension classification | 0.251 | 1.552 (0.732–3.290) |
| BMI | 0.405 | 0.943 (0.890–0.987) |

Note: *P-value <0.05.
Abbreviations: OR, odds ratio; CI, confidence interval; BMI, body mass index.

the surgical techniques used were predictors for the remission of hypertension.

Bariatric surgery is a mature and widely accepted surgical technique worldwide. Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) are the main surgical techniques. It has been reported that bariatric surgery can cause weight loss, and even acquire the improvement in diabetes, hyperlipidemia, hypertension, and heart function.

Radical gastrectomy plus lymphadenectomy is the currently widely accepted surgical technique for patients with resectable gastric cancer. The bariatric surgery has been proven to improve metabolism-related diseases. In gastrectomy, the magnitude of the stomach incision is no less than that in bariatric surgery, so there may be some improvement in concurrent gastric cancer and metabolism-related diseases. Patients with concurrent gastric cancer and diabetes can exhibit remission of diabetes after gastrectomy.

It was thought that gastrectomy is not just a tumor resection surgery, but also an onco-metabolic surgery. However, patients with concurrent gastric cancer and hypertension after gastrectomy have rarely been reported. Weight loss was obtained after bariatric surgery and was a parameter for the remission of hypertension in previous studies. However, in this study, weight loss seemed to be a negative parameter for the remission of hypertension. Consistent with a previous report, lifestyle modifications, such as sodium absorption dysfunction, may play an important role beyond weight loss.

Age is another parameter for the remission of hypertension in patients with concurrent gastric cancer and hypertension. It was also reported that after bariatric surgery, the blood pressure of younger patients decreased more significantly than that of older patients. A comprehensive meta-analysis reported similar conclusions. Age was not a parameter for the remission of hypertension in patients with concurrent gastric cancer and hypertension in the previous literature; the possible reason is that one article did not have complete baseline information, while the other article had a relatively small amount of data. In this study, younger patients tended to have better rates of hypertension remission than older patients. Postoperative lifestyle and vascular elasticity may play an important role in younger patients who exhibit remission of hypertension. Furthermore, younger patients may have a short duration of hypertension, which contributes to better remission of hypertension.

Different bariatric surgical techniques for metabolic diseases were compared, and some significant differences were proposed. We compared the differences between total gastrectomy and subtotal gastrectomy in this study, and different reconstruction methods for subtotal gastrectomy were compared as well. As a result, total gastrectomy can predict remission of hypertension, and the reconstruction methods for subtotal gastrectomy had no relevance with regards to the remission of hypertension. An article reported that there was no significant difference in the amount of food consumed after different surgical techniques in patients with gastric cancer. The difference between total gastrectomy and subtotal gastrectomy may be due to the volume of the residual stomach. Total gastrectomy allows less storage of food, which may cause better remission of hypertension. Total gastrectomy could be a recommended surgical technique in patients with concurrent gastric cancer and hypertension.

The molecular mechanism of remission of hypertension after bariatric surgery is currently complex and unclear. It was recently proposed that multiple factors work together to cause remission of hypertension. Early remission may be related to endocrine hormones, and long-term remission may be related to neurohumoral. Regarding the specific mechanism for the remission of hypertension after gastrectomy, a lack of endocrine hormones is important, and more experiments need to be carried out in the future.

There are some limitations to this study. First, this study was a retrospective study. Second, the follow-up time of this study was short, only 6 months, and some indicators, such as the duration of preoperative hypertension, postoperative dietary changes, and lifestyle differences, were lacking. There should be a prospective study in the future, and a long-term follow-up should be carried out. In addition, some blood measurements before and after gastrectomy should be taken into consideration in the subsequent experimental designs.
In conclusion, total gastrectomy is an onco-metabolic surgery that can cure younger patients with concurrent gastric cancer and hypertension. Age and the surgical techniques used can predict the remission of hypertension 6 months after gastrectomy.

**Abbreviations**

DM, diabetes mellitus; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blockers; RYGB, Roux-en-Y gastric bypass; SG, sleeve gastrectomy.

**Data Sharing Statement**

The data of this study are available upon special request to the corresponding author(s).

**Ethics Approval and Consent Statement**

This study was conducted in accordance with the World Medical Association Declaration of Helsinki and was approved by the Medical Ethics Committee of the First Affiliated Hospital of Chongqing Medical University.

**Consent for Publication**

All patients signed the informed consent to participate in this study.

**Acknowledgments**

The authors are grateful for all the colleagues who helped in the preparation of this article. Dong Peng and Yu-Xi Cheng are co-first authors for this study.

**Author Contributions**

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

**Funding**

Basic and frontier research program of Chongqing (cstc2016jcyja0355).

**Disclosure**

The authors declare that they have no competing interests.

**References**

1. Karimi P, Islami F, Anandasabapathy S, Freedman ND, Kamangar F. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. *Cancer Epidemiol Biomarkers Prev.* 2014;23(5):700–713. doi:10.1158/1055-9966.EPI-13-1057
2. Chen W, Zheng R, Baade P, et al. Cancer statistics in China, 2015. *CA Cancer J Clin.* 2016;66(2):115–132. doi:10.3322/caac.21338
3. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). *Gastric Cancer.* 2017;20(1):1–19. doi:10.1007/s10120-016-0622-4
4. Mcnair AG, Blazey JM. Health-related quality-of-life assessment in GI cancer randomized trials: improving the impact on clinical practice. *Expert Rev Pharmacoecon Outcomes Res.* 2009;9(6):559–567. doi:10.1586/erp.09.68
5. Lim S, Vos T, Flaxman A, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet.* 2012;380(9859):2224–2260. doi:10.1016/S0140-6736(12)61766-8
6. Global A. Brief on Hypertension: Silent Killer, Global Public Health Crisis. Geneva, Switzerland: World Health Organization; 2013.
7. WHO. *Global Health Risks*. WHO Libr Cat Data Glob; 2009:1–70. ISBN 978 92 4156387 1.
8. Lu J, Lu Y, Wang X, et al. Prevalence, awareness, treatment, and control of hypertension in China: data from 1.7 million adults in a population-based screening study (China PEACE million persons project). *Lancet.* 2017;390(10112):2549–2558. doi:10.1016/S0140-6736(17)32478-9
9. Frieden TR, Jaffe MG. Saving 100 million lives by improving global treatment of hypertension and reducing cardiovascular disease risk factors. *J Clin Hypertens.* 2018;20(2):208–211. doi:10.1111/jch.1195
10. Ricci C, Gaeta M, Rausa E, Macchitella Y, Bonavina L. Early impact of bariatric surgery on type II diabetes, hypertension, and hyperlipidemia: a systematic review, meta-analysis and meta-regression on 6587 patients. *Obes Surg.* 2014;24(4):522–528. doi:10.1007/s11695-013-1121-x
11. Sarkhosh K, Birch DW, Shi X, Gill RS, Karmali S. The impact of sleeve gastrectomy on hypertension: a systematic review. *Obes Surg.* 2012;22(5):832–837. doi:10.1007/s11695-012-0615-2
12. Lee EK, Kim SY, Lee YJ, et al. Improvement of diabetes and hypertension after gastrectomy: a nationwide cohort study. *World J Gastroenterol.* 2015;21:1173–1181. doi:10.3748/wjg.v21.i4.1173
13. Kim HJ, Cho EJ, Kwak MH, et al. Effect of gastrectomy on blood pressure in early gastric cancer survivors with hypertension. *Support Care Cancer.* 2019;27(6):2237–2245. doi:10.1007/s00520-018-4491-8
14. Casey DE, Thomas RJ, Bhalla V, et al. 2019 AHA/ACC clinical performance and quality measures for adults with high blood pressure: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. *J Am Coll Cardiol.* 2019;74:2661–2706. doi:10.1016/j.jacc.2019.10.001
15. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver. 3). *Gastric Cancer.* 2011;14(2):113–123. doi:10.1007/s10120-011-0042-4
16. Manan, Pareek, Deepak, et al. Metabolic surgery for hypertension in patients with obesity. *Circ Res.* 2019;124(7):1009–1024.
17. Chang SH, Stoll CR, Song J, Varela JE, Eagon CJ, Colditz GA. The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003–2012. *JAMA Surg.* 2014;149:275–287. doi:10.1001/jamasurg.2013.5654
18. Schiavon CA, Ikeoka DT, de Sousa MG, et al. Effects of gastric bypass surgery in patients with hypertension: rationale and design for a randomised controlled trial (GATEWAY study). BMJ Open. 2014;4(9):e005702. doi:10.1136/bmjopen-2014-005702

19. Gloy VL, Briel M, Bhatt DL, et al. Bariatric surgery versus non-surgical treatment for obesity; a systematic review and meta-analysis of randomised controlled trials. BMJ. 2013;347(oct22 1):f5934. doi:10.1136/bmj.f5934

20. Eliasson B, Liakopoulos V, Franzen S, et al. Cardiovascular disease and mortality in patients with type 2 diabetes after bariatric surgery in Sweden: a nationwide, matched, observational cohort study. Lancet Diabetes Endocrinol. 2015;3(11):847–854. doi:10.1016/S2213-8587(15)00334-4

21. Sasaki M, Sano T, Yamamoto S, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med. 2008;359(5):453–462. doi:10.1056/NEJMoa0707035

22. Wang K-C, Huang K-H, Lan Y-T, et al. Outcome after curative surgery for gastric cancer patients with type 2 diabetes. World J Surg. 2014;38(2):431. doi:10.1007/s00268-013-2291-3

23. Zhu Z, Shan X, Cheng Y, et al. Clinical course of diabetes after gastrectomy according to type of reconstruction in patients with concurrent gastric cancer and type 2 diabetes. Obes Surg. 2015;25(4):673–679. doi:10.1007/s11695-014-1426-4

24. Lee TH, Lee CM, Park S, et al. Long-term follow-up for type 2 diabetes mellitus after gastrectomy in non-morbidly obese patients with gastric cancer: the legitimacy of onco-metabolic surgery. J Gastric Cancer. 2017;17:283–294. doi:10.5230/jgc.2017.17.e34

25. Carlin AM, Yager KM, Rao DS. Vitamin D depletion impairs hypertension resolution after Roux-en-Y gastric bypass. Am J Surg. 2008;195:349–52; discussion 352. doi:10.1016/j.amjsurg.2007.12.016

26. Sugerman HJ, Wolfe LG, Sica DA, et al. Diabetes and hypertension in severe obesity and effects of gastric bypass-induced weight loss. Ann Surg. 2003;237:751–6; discussion 757–8. doi:10.1097/01.SLA.0000071560.76194.11

27. Jeon TY, Lee S, Kim HH, et al. Long-term changes in gut hormones, appetite and food intake 1 year after subtotal gastrectomy with normal body weight. Eur J Clin Nutr. 2010;64(8):826–831. doi:10.1038/ejcn.2010.83

28. Schiavon CA, Drager LF, Bortolotto LA, et al. The role of metabolic surgery on blood pressure control. Curr Atheroscler Rep. 2016;18(8):50. doi:10.1007/s11883-016-0598-x

29. Ahmed AR, Rickards G, Coniglio D, et al. Laparoscopic Roux-en-Y gastric bypass and its early effect on blood pressure. Obes Surg. 2009;19(7):845–849. doi:10.1007/s11695-008-9671-z

30. Drucker DJ. The role of gut hormones in glucose homeostasis. J Clin Invest. 2007;117(1):24–32. doi:10.1172/JCI30076